The new platform will help diagnostic test manufacturers to monitor performance of SARS-CoV-2 assays, according to the firm. Its development is in response in part to the U.S. Food and Drug Administration's January warning that molecular tests for the detection of SARS-CoV-2 may produce false-negative results if a mutation occurs in the part of the virus's genome gauged by that test, Rosalind said.

The company developed DxM under the auspices of the Rapid Acceleration of Diagnostics (RADx) Tech program, which is part of the U.S. National Institutes of Health's RADx initiative launched in April 2020.

Dyadic, Medytox to develop COVID-19 vaccines against variants
Dyadic International and South Korean biopharmaceutical firm Medytox have partnered to co-develop C1-enabled vaccines and boosters that will immunize...

Stable spike protein makes main SARS-CoV-2 variant more infectious
A new study finds that the enhanced infectivity of the dominant G614 variant of the SARS-CoV-2 virus largely results from the increased stability of its...

Moderna doses 1st patients in COVID-19 vaccine booster trial
Moderna has dosed the first patients in its study of modified COVID-19 vaccines, designed to address the potential need for vaccine booster candidates.

CEPI, VBI to develop COVID-19 vaccine against variants
The Coalition for Epidemic Preparedness Innovations (CEPI) will support the development of enveloped viruslike particle vaccine candidates against SARS-CoV-2...